edik
27 Sep 2016
Re: Can't buy Got in at 1.36
velocipede
27 Sep 2016
Re: Now up 152% - veloc the top of what, asilad?
edik
27 Sep 2016
Can't buy It asks me to place an order... from experience that's not a good idea
asilad
27 Sep 2016
Re: Now up 152% - veloc You must have bought in very near the top so could go either way. Longer term though, this is a cracking result for the company.Good luck.
velocipede
27 Sep 2016
Re: Now up 152% Phew - just got in ten minutes ago. Hope I was in time......
suka47
27 Sep 2016
Now up 152% n/m
HPC Follower
27 Sep 2016
Re: Up 60% - why? Thanks suka47 - the RNS is still not out on III. And, now up 80%... should have bought more perhaps over recent years, but at least I am showing a profit now.
suka47
27 Sep 2016
Re: Up 60% - why? Look at RNS
HPC Follower
27 Sep 2016
Up 60% - why? Good news must be out - buy what/where?
suka47
27 Sep 2016
RNS Good News (AIM: SAR)27 September 2016SAREUM HOLDINGS PLC("Sareum" or "the Company"
Licence agreement for Chk1 Inhibitor CCT245737Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that its co-investment partner, the CRT Pioneer Fund, has today licensed exclusive and worldwide rights for the Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) to ProNAi Therapeutics, Inc. (NASDAQ: DNAI).Under the terms of the agreement, an immediate upfront payment of US$7.0 million is due to the co-investment partners and an additional fee of up to US$2.0 million will be payable upon the successful transfer of the two ongoing Phase 1 clinical trials to ProNAi. Additional payments in the aggregate amount of up to US$319.5 million may become payable upon achievement of certain development, regulatory and commercial milestones. ProNAi will also owe high single to low double digit royalties on the net sales of any product successfully developed.Under Sareum's agreements with Cancer Research Technology and the CRT Pioneer Fund, Sareum is entitled to 27.5% of these payments. Therefore, Sareum will receive (i) US$1.9 million as an upfront payment, (ii) potential future milestone payments of up to US$88.4 million, some of which are expected to be paid within the next twelve months upon certain development milestones being met and (iii) its share of any sales royalties. Furthermore, the unspent balance, estimated at c£300,000, of the financial commitment to the trial funding of £797,500 made by Sareum in December 2015 will be returned to the Company.ProNAi is a well-funded clinical stage drug development company advancing targeted therapeutics for the treatment of patients with cancer. The company is comprised of a highly respected management team with a proven track record of success in oncology drug development.PNT737 was originally developed in a research collaboration between the Institute of Cancer Research, London (ICR), Sareum Limited and Cancer Research Technology Ltd (CRT). The Programme was licensed to the CRT Pioneer Fund in September 2013 and a co-investment partnership with Sareum was formed to progress the candidate drug through clinical trials. Dr Tim Mitchell, CEO of Sareum commented, "This is a major achievement for our lead candidate as well as for Sareum. Starting with the initial discovery, we have contributed financially and scientifically to the ongoing development of the programme into clinical trials. The returns from this research investment will be realised in this licence agreement, validating our strategy and business model. ProNAi is in a strong position to further the development of PNT737 and plans to expand its development into the United States and with broader clinical studies. We look forward to reporting on their progress.""This is another significant milestone on the development path for this promising Chk1 inhibitor. We recently initiated a Phase 1 single agent monotherapy study and a Phase 1 study of PNT737 in combination with DNA-targeting chemotherapies. ProNAi has a world-class oncology development team and is well-capitalized, and we believe these studies and the ongoing development strategy for this drug are in excellent hands," added Dr Robert James, Managing Partner of Sixth Element Capital LLP, managers of the CRT Pioneer Fund.This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014. For further information, please contact:Sareum Holdings plc
one4all
26 Aug 2016
news Tuesday, watch this space BUY
one4all
25 Aug 2016
would be nice to see 4% per week up to some trials news ... then boom
one4all
03 Aug 2016
so the point f the speeding ticket last week? seems like last weeks speeding ticket was a joke given that they were pending this news on patents. i just scratch my head an wonder sometimes... a speeding ticket when the price just rises to the level of the last fund raise... you couldnt make it up
one4all
28 Jul 2016
how to hack off investors issue an RNS when the share price gets back to where they last soaked investors for a fund raise to tell us that the article which didn't know about was old news.wrong on so many levels.firstly. why don't they issue an RNS when the share price goes down 25% to tells us they are ok and don't know the reason for the drop..consistency..secondly they are admitting that they didn't know about an article from their key partner..really..thirdly YOU RAISED MONEY AT .7p whats wrong with people republishing articles on BBs even if they are old and they are doning your PR job and YOU RAiSED MONEY AT .7p
Ripley94
27 Jul 2016
Re: COULD BE A BIG BIG DAY! Any reason for thinking that alltold9 ?
